Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Myovant Sciences Recent News is Good for Prostate Cancer Patients

June 3, 2020 0

Myovant Sciences Good News A lot of positive news is emanating from clinical trials conducted by …

Compugen: Predictive Computational Discovery Technology

June 1, 2020 0

Compugen IND Application for Triple Combination Study Cleared by the US FDA The U.S. Food and …

Why Sonoma Pharmaceuticals and Adaptimmune Stock Prices Skyrocketed

May 29, 2020 0

Sonoma Pharmaceuticals and MicroSafe Group, Dubai Sonoma Pharmaceuticals (SNOA) develops stabilized hypochlorous acid (HOCl) products for …

Questions & Answers

May 27, 2020 0

The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for …

Encouraging Results From Nektar’s Product BEMPEG: NKTR-214 In Combination with the Checkpoint Inhibitor Nivolumab

May 22, 2020 0

Nektar Therapeutics Nektar Therapeutics (NKTR) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, …

Navidea Biopharmaceuticals: Why This Small Firm’s Stock Skyrocketed

May 22, 2020 0

Navidea Biopharmaceuticals Stock Soared Navidea Biopharmaceuticals (NAVB) stock price jumped from $1.27 to $3.04 this morning. …

Gilead Sciences and Galapagos NV: Good News from Filgotinib in Ulcerative Colitis

May 21, 2020 0

Gilead Sciences and Galapagos NV Announce Good News from Filgotinib Trial Gilead Sciences (GILD) and Galapagos …

Inovio: INO-4800 DNA Vaccine Against the Novel Coronavirus Has Promising News. Moderna Still Has the Front-Runner

May 20, 2020 0

Inovio DNA Vaccine Candidate INO-4800 for SARS-CoV-2 Inovio (INO) announced the publication of the preclinical study …

Moderna: Pricing of a Public Offering of 17,600,000 Shares at $76.00 Per Share

May 19, 2020 0

Moderna Inc: A Public Offering Moderna (MRNA) announced the pricing of an underwritten public offering of …

Moderna: Positive Interim Phase 1 Data for its mRNA-1273 Vaccine Against Novel Coronavirus

May 18, 2020 0

Moderna Postive News for mRNA-1273 Vaccine Against Novel Coronavirus (COVID-19) Moderna (MRNA) announced positive interim clinical …

Sorrento Therapeutics: STI-1499 ~ An Encouraging Anti-SARS-CoV-2 Antibody

May 16, 2020 0

Sorrento Therapeutics Anti-SARS-CoV-2 Antibody STI-1499 Sorrento Therapeutics (SRNE) announced that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% …

Bristol-Myers Squibb and bluebird bio Product Ide-Cel, Bb2121 and the FDA Refusal Letter. What Do We Expect?

May 13, 2020 0

Bristol-Myers Squibb and bluebird bio Bristol-Myers Squibb (BMY) and bluebird bio (

Novavax: A Profile and a Comment. See Also: Why We Need More Firms to Develop Coronavirus Vaccines

May 13, 2020 0

Novavax Still Rallying After Grant The Grant That Continues To Rally the Stock Novavax (NVAX) stock …

The Impacting News of the Day

May 12, 2020 0

Impacting News from Novavax, CymaBay Therapeutics and Sanofi SA Novavax The Grant That Rallied the Stock …

Novel Coronavirus: The Therapeutics

May 11, 2020 0

Prohost Letter #440 Coronavirus The Therapeutics Gilead’s Remdesivir Treating COVID-19 patients requires therapeutic products that can …

Pluristem Therapeutics: The FDA Cleared Phase 2 Study of Its PLX Cells in Treating the Respiratory Complications of COVID-19

May 8, 2020 0

Pluristem Therapeutics IND Cleared by FDA for PLX Cells in COVID-19 Treatment From Pluristem Therapeutics (PSTI) …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Myovant Sciences Recent News is Good for Prostate Cancer Patients

Compugen: Predictive Computational Discovery Technology

Why Sonoma Pharmaceuticals and Adaptimmune Stock Prices Skyrocketed

Questions & Answers

Encouraging Results From Nektar’s Product BEMPEG: NKTR-214 In Combination with the Checkpoint Inhibitor Nivolumab

Navidea Biopharmaceuticals: Why This Small Firm’s Stock Skyrocketed

Gilead Sciences and Galapagos NV: Good News from Filgotinib in Ulcerative Colitis

Inovio: INO-4800 DNA Vaccine Against the Novel Coronavirus Has Promising News. Moderna Still Has the Front-Runner

Moderna: Pricing of a Public Offering of 17,600,000 Shares at $76.00 Per Share

Moderna: Positive Interim Phase 1 Data for its mRNA-1273 Vaccine Against Novel Coronavirus

Sorrento Therapeutics: STI-1499 ~ An Encouraging Anti-SARS-CoV-2 Antibody

Bristol-Myers Squibb and bluebird bio Product Ide-Cel, Bb2121 and the FDA Refusal Letter. What Do We Expect?

Novavax: A Profile and a Comment. See Also: Why We Need More Firms to Develop Coronavirus Vaccines

The Impacting News of the Day

Novel Coronavirus: The Therapeutics

Pluristem Therapeutics: The FDA Cleared Phase 2 Study of Its PLX Cells in Treating the Respiratory Complications of COVID-19

The FDA Cleared Moderna’s Coronavirus Vaccine for a Phase 2 Trial. The Stock Surged in Pre-market Hours

Alexion Pharmaceuticals to Acquire Portola at $18 Per Share

Applied DNA Sciences and Takis Biotech: A DNA Vaccination Injection in Animals Induced Antibodies That Block SARS-CoV-2

The Time Has Come for This Small Biotech Firm to Grow and Thrive